Insulin suspension isophane/insulin biosimilar - Julphar

Drug Profile

Insulin suspension isophane/insulin biosimilar - Julphar

Alternative Names: Biosimilar human normal insulin/protaminated insulin suspension - Julphar; Human biphasic insulin - Julphar; Insulin human 30/70 - Julphar; Julphar Insulin 30/70; Jusline 30/70; Recombinant human insulin/protamine insulin mixture - Julphar

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Julphar Gulf Pharmaceutical Industries
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus

Most Recent Events

  • 01 Jun 2016 Julphar completes a phase I trial for Diabetes mellitus in Germany (SC) (NCT02631928)
  • 01 Feb 2016 Phase-I clinical trials in Diabetes mellitus (In volunteers) in Germany (SC) (NCT02631928)
  • 25 Nov 2015 Julphar plans a phase I trial for Diabetes mellitus in Germany (SC) (NCT02631928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top